There has been increasing pressure for systemization in cytopathology. Lack of uniformity in categorization, variation in opinion based regional practice, and technologic advancement have created an environment disposed toward creation of more consistent evidence-based approaches to diagnostic problems. This review provides an overview of the major standardized terminology systems in cytology, with historical perspectives and commentary on current uses of these systems. These systems now include gynecologic, thyroid, pancreaticobiliary, urinary, salivary gland, and breast cytology. We summarize major classification systems supported by national and international professional organizations, outlining the structure and goals of each system. Specific benefits and potential pitfalls in the implementation of each system are given. 
| INTRODUCTION
The practice of cytology as specialty has evolved over the last 70 years, a century junior to the histologic approach of the 1850's. With the development and popularization of cytologic methods, the practice of cytopathology has evolved significantly. More than a half-century of literature expounds on the strengths and limitations of our samples and diagnoses. With maturity, the attention of authorities in cytology has focused on the reproducibility of cytologic diagnoses, risk of malignancy (ROM) associated with a given interpretation, and the clarity of communication with our clinical colleagues. This review gives an overview of the major standardized terminology systems in cytology, with historical perspectives and commentary on current uses of these systems.
The sections that follow summarize major classification systems supported by national and international professional organizations, outlining the structure and goals of each system. Specific benefits and potential pitfalls in the implementation of each system are given.
Finally, we address potential criticisms of standardized terminology systems and proposed future directions to continue the evolution of standardized terminology to improve clinical practice.
This review of systems is not all-encompassing. It is recognized that this article does not address every cytologic system generated from every country and in every language. The systems examined are largely the product of collaborations beginning at meetings of major cytologic organizations, involve representatives of the American Society of Cytopathology and the International Academy of Cytology, and tend to be developed in English.
| WHAT MOTIVATES STANDARDIZATION IN CYTOPATHOLOGY?
The efforts at standardization in these cytologic systems came about because of new knowledge and particular problems that needed to be addressed. Common to all was the need to establish a common language for pathologists, clinicians, and laboratory information systems Importantly, consistency will engender trust in the cytologic method for our histopathological and clinical colleagues.
The benefits standardized terminology brings to communication are clear. When communicating with other pathologists, both within an institution and between institutions, a physician can be more certain that they are referring to comparable diagnostic entities with similar risks of malignancy. This communication benefit extends beyond national borders, as international input is sought in the development of these terminology systems. The standardized terminology itself can help in maintaining diagnostic integrity across language barriers. In communicating with clinicians, the standardized terminology system is usually accompanied by recommendations for standardized report structure, which may reduce the rate of clinician errors in interpreting the pathology report. 1 In communicating with patients, standardized terminology has a greater likelihood of leading the internet-savvy patient to information appropriate to their diagnosis.
Adding value and meaning for both patients and clinicians, standardized terminology is generally accompanied by predictions of ROM as well as better integration with management guidelines. The standardized terminology systems also tend to focus on pathologists'
efforts on the areas of highest clinical utility, such as the detection of high grade urothelial carcinoma (HGUC) in the Paris system rather than low grade urothelial neoplasms. 2 In the area of quality assurance, standardized terminology facilitates laboratory information system searches and the observation of established metrics, 3 such as the atypical cells of uncertain significance:squamous intraepithelial lesion (ASCUS:SIL) ratio in gynecologic (GYN) cytology 4 and the atypia of uncertain significance (AUS) rate in cytology. 5 The ease of generating these metrics can also allow laboratories to identify and quantify specific areas for improvement based on specific areas of concern, either lab-wide or for individual cytotechnologists and pathologists. Standardized terminology also eases cytology-histology correlation, making it easier to algorithmically define which cytology cases are discordant and need review.
Beyond intralaboratory quality assurance, standardized terminologies have the potential to help improve reproducibility in the field of cytology as a whole. The Bethesda System for Reporting Cervical Cytology (TBS-GYN) has seen improving reproducibility over time, as evidenced by 2 international online surveys. 6, 7 Standardized terminology also creates opportunities for research. 
| BARRIERS TO ADOPTING STANDARDIZED TERMINOLOGY, AND PROPOSED SOLUTIONS
Although the benefits of adopting standardized terminology systems are many, pathologists may face significant barriers to the adoption of standardized terminology. In some cases, clinical, radiographic information, or ancillary studies necessary to precisely match the diagnostic criteria may not be available. 9 It is still possible to convey uncertainty within standardized terminology systems through the use of explanatory comments. Additional morphologic description and differential diagnostic considerations can be included where relevant.
There may be concern that a change in terminology may be unwelcome for clinicians. The decision to change terminology should certainly be undertaken jointly with the clinicians who frequently request cytology. Educational programs should be offered.
Clinicians may be less aware of advances in cytology and the potential benefits offered by standardized terminology. Clinician input is sought in the generation of standardized terminology systems through surveys, 10 and inclusion in interdisciplinary discussions and publication efforts. For example, endocrinologist input was included on the international panel for TBS-Thyroid. 11 Pathologists may present standardized terminology to clinicians in terms of how it will affect clinical utility of the test and integration into management guidelines. Any clinically relevant details not covered by the standardized terminology could be agreed to be reported in the comment section of the report.
Although change may be desired, the logistical aspects of implementing a standardized terminology system may be prohibitive. 
| HOW WERE THE SYSTEMS CREATED?
There are common threads in the generation of these systems ( Figure 2 ). One or 2 leaders in a field proposed a problem and brought it to other experts who agreed on a need (Table 1) . Then support for the creation of a system was obtained from a larger entity and committees or "task-forces" were formed. In the case of TBS-GYN and initially TBS-Thyroid, it was the government, through the good offices of the National Cancer Institute with meetings held on the NIH campus
The creative cycle: The flowchart above provides a general outline for the standardized terminology projects. All of the projects start due to the efforts of 1 or 2 experts who then collected others interested in the specific problem or area of specialty. After expert panel discussions, the cytopathology community is surveyed via web-based tools for comment and likelihood of acceptance of a proposed terminology system. Categories with criteria and explanatory notes are drafted while atlas images were being collected. All development from conception to publication tends to occur in a 2-to 3-year cycle As each of the major system publications came out as an atlas, it was important that contributed images be carefully selected, uniformly sized, color balanced, and sharpened prior to submission. It is useful to have an interested pathologist convert the submitted image material into consistent sizes and file types for inclusion into manuscripts. In development of the systems it was often the case that some images were too small and did not contain enough information for inclusion or were far too large and contained more information necessary for the printed page. A common image file specification for these systems was 5 by 7 in. at 300 dots per inch (dpi). Uniform image quality and color balance are important to the development of these atlases, and suitable application for photo editing include Adobe
Photoshop (San Jose, CA), GIMP (www.gimp.org), PixLr (www.pixlr.
com), Paint.net (www.getpaint.net), and SumoPaint (www.
sumopaint.com).
| BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY
The first and best known of the modern reporting systems is the
Bethesda System for Reporting Cervical Cytology (TBS-GYN). The
Pap Test and advent of mass public screening decreased uterine cancer deaths (the majority of which were cervical squamous-cell carci- (CLIA 88). TBS-GYN was incorporated as the method of reporting. 16 The initial TBS-GYN categories reflected descriptive diagnoses commonly used in cervical cytology, with a statement of adequacy and diagnostic categories ranging from infectious organisms to dysplasia to carcinoma (Table 2) . 16 To meet the demand for Pap smear testing, gynecologic cytology is practiced by cytotechnologists, general pathologists, as well as certified cytopathologists. Getting all of these individuals to be able to categorize cytologic samples in the same way The reporting of endometrial cells has also evolved. Pre-Bethesda tended to report all occurrences of benign-appearing endometrial cells after day 12 of the menstrual cycle and suggest that these cells were occurring out of phase. In the Bethesda era, the improved sampling devices tended to reach deeper into the cervical canal to adequately sample the transformation zone. Lower uterine segment with its endometrial epithelium was more often inadvertently sampled and had less relation to physiologic shedding. 19 The earliest incarnation of TBS-GYN required the reporting of endometrial cells in Pap tests for any post-menopausal woman. Menopausal status is often imprecise or unavailable, the second edition of TBS-GYN (2001) recommended follow-up for women 40 and older who exhibited benign endometrial cells in their cervical cytologic samples, due to concern for risk of endometrial hyperplasia or carcinoma in these patients. Subsequent work found that this age was too low, and that significant numbers of women were worked up unnecessarily. 20 Currently, TBS-GYN suggests that reporting of benign-appearing endometrial cells begin in (Table 3) . 11 Several timely alterations were proposed. Adjustments to the reported ROM for each The Malignant category showed an absolute decrease in ROM of 3%-5%. Based on updated data, the recommended maximum rate of AUS/FLUS diagnosis was increased from 7% to 10% in the 2018 TBS-Thyroid.
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TBS-Thyroid also facilitates the study of new techniques, both within pathology and outside of pathology. In thyroid imaging, TBSThyroid may be combined with ultrasound-based risk stratification such as American Thyroid Association guidelines 28 or the Thyroid Imaging Reporting And Data System (TIRADS), 29 with great potential to improve imaging prediction and appropriate test utilization. 30 Within pathology, digital cytopathology has been evaluated using TBS-Thyroid to evaluate performance. 31 TBS-Thyroid's separation of AUS/FLUS diagnoses allows targeted evaluation of the clinical utility and cost-effectiveness of molecular testing.
32-34
Overall, TBS-Thyroid has seen widespread use in the cytology community and continues to evolve with user input, increasing data on ROM, and changes in surgical pathology diagnoses. It is a prototype for the successful application of standardized terminology to non-gynecologic specimens. The categorization scheme for pancreaticobiliary cytology was based on 6 tiers and is shown in Table 4 . Alternatively, high grade lesions that are relatively easy to see on cytology tend to be flat and hidden from the cystoscope. 40 as distinct from the more genetically unstable high grade lesions that are characterized by p53 mutation. 41 Third, that the histologic classification of some low grade lesions as "cancer"
| THE PAPANICOLAOU SOCIETY SYSTEM FOR REPORTING PANCREATICOBILIARY CYTOLOGY
is a misnomer. If such neoplasms do not invade or metastasize they do not meet the definition of malignancy as a lesion capable of local invasion and distant spread. 2, 42 The use of the term "cancer" for these lesions has an effect on the psychology of both patients and clinicians, yielding both fear and urgency that may not be so warranted. Fourth, the use of overuse of the atypia category was widespread and impaired the performance characteristics of the test. 43 Any system needs to find ways to restrict the use of atypia to lesions that have some significant ROM. Fifth, and most importantly that the object of urinary cytology should be restricted to what is does best, which is the detection and diagnosis of HGUC.
TPS was built around those ideas. The diagnostic categories are listed in Table 5 . All cytologic findings that are not worrisome for high grade urothelial neoplasia are classified as Negative for High Grade 
| THE MILAN SYSTEM FOR REPORTING SALIVARY GLAND CYTOPATHOLOGY
Building on the success of prior classification systems for other organs, the Milan System for Reporting Salivary Gland Cytopathology (TMS) was developed as a joint effort of the ASC and the IAC by a taskforce of international representatives that first met in Milan, Italy, in 2015. 46 The premise was that Salivary Gland FNA is an effective method for the initial evaluation of salivary gland lesions, but prior to
Milan there was no uniform widely accepted reporting system. The effort is backed by a large body of literature explaining salivary gland FNA utility, but the authors were mindful that the complexity of salivary gland cytology presents unique problems. The set of lesions with basaloid features and other tumors of uncertain biologic potential required a special categorization somewhat similar to the "neoplasm:
other" of the pancreaticobiliary guidelines. In Milan, these lesions were termed Salivary gland tumors of Uncertain Malignant Potential or SUMP and includes entities worrisome for malignancy on the basis of indeterminate cytomorphology and when the cytologic pattern is not consistent with the clinical or radiologic findings. The major diagnostic categories are shown in Table 6 . Initial surveys to the greater cytology community formed the basis of the initial effort, 12 and the atlas was published in 2018.
A major goal of TMS is to improve cytologic guidance of clinical decision making. 46 As such, the diagnostic categories reflect the major surgical planning decision points. Particularly, nonneoplastic lesions do not require surgical excision, while benign neoplasms may benefit from conservative excision. Among malignant neoplasms, the categorization of low grade vs high grade malignancies may dictate whether the facial nerve is sacrificed or spared, or whether lymph node dissection will be pursued. 46 In addition to improving the clinical utility of salivary gland diagnostic reporting, TMS also seeks to improve interobserver reproducibility. In an institutional study, a simplified categorization system similar to TMS shows improved interobserver reproducibility over a more detailed, pattern-based categorization system. 47 An international, web-based interobserver reproducibility study, the Milan Interobserver Reproducibility Study (MIRST), has been completed and reporting of results is anticipated in mid-late 2018. 48 TMS does not yet establish adequacy criteria for salivary gland cytology, although even paucicellular or acellular specimens can be considered adequate if matrix or mucin is present suggestive of a neoplasm. 46 Adequacy criteria from TBS-Thyroid are suggested as a starting point for most specimens. TMS will no doubt continue to evolve as laboratories begin to implement the system prospectively.
| THE INTERNATIONAL ACADEMY OF CYTOLOGY YOKOHAMA STANDARDIZED REPORTING SYSTEM FOR BREAST CYTOLOGY
Breast FNA has been decreasing in the United States due to the widespread use of core-needle biopsy, which provides tissue architecture to assess invasion as well as tissue for biomarker testing. However, FNA has some advantages, including shorter patient wait times, lower rates of complications, and the ability to perform immediate evaluation. 49, 50 In developing countries, encompassing about 80% of the world, there is limited access to imaging modalities and tissue processing necessary for histopathologic examination of core-needle biopsies. 49, 51 Thus, breast FNA remains the most accessible diagnostic modality for these populations.
The International Academy of Cytology (IAC) has proposed the Yokohama Standardized Reporting System for Breast Cytology, which is still in its preliminary phases. The system seeks to guide practitioners toward best practices in indications for biopsy, specimen preparation techniques, standardized reporting, appropriate use of ancillary studies, and recommendations for clinical management. 51, 52 The system will contain 5 diagnostic categories: Insufficient Material;
Benign; Atypical, Probably Benign; Suspicious for Malignancy, Probably In Situ or Invasive Carcinoma; and Malignant. 49, 51 The Atypical and Suspicious categories particularly recognize the difficulty in distinguishing proliferative lesions from ductal carcinoma in situ and invasive carcinoma on cytology. 51 The Yokohama system draft is expected to be released on the IAC website in 2018.
| CONCLUSIONS
In this review, we have detailed the rationale and history behind recent standardized terminology systems in cytology and provided an update on features of interest in the current systems for gynecologic, thyroid, pancreaticobiliary, salivary gland, and breast cytology. While a few pathologists may feel reluctant to adopt standardized terminology, the continual improvement of these systems offers myriad benefits to practicing pathologists and to the field of cytology as a whole.
To be clinically relevant cytology has to deliver a consistent clear message with interpretations based on useful evidence-based information. There is no diagnostic method that can survive with a plethora of individuals at different centers or within the same center giving different or unclear messages to the people who are managing patients.
The standard terminology systems were created to address problems within cytologic disciplines and to unify expectations for reporting cytologic interpretations.
There is a range of performance in any field of endeavor, and it does not appear to be a bell-shaped curve. There are rare artistic geniuses at the high end who perform at an exceptional level secondary to an excellent knowledge base and superior cortical wiring. Alternatively, there is the great body of practitioners who need external support and organization to meet the level performance needed to provide acceptable care. Even the genius will not be able to bestow his or her gifts if they are not speaking the same language as the people that their efforts are directed toward. There are wide variances in opinions about and practices in cytology. The pre-publication Milan study for salivary gland practice was a good example. 41 This variability can only have a negative effect on our clinical and histopathological colleagues. The standardized terminology systems intend to generate useful, clearer, and consistent messages to the rest of medicine. With the advent of molecular medicine, our messages become more important, because tremendous amounts of important information can be generated from small samples. That is, if we have the right small sample, and if we are diagnostically dependable.
Cytology is not alone in needing to deliver uniform, stable systems. Because of clinical demand surgical pathology has evolved synoptic reports, enforced by national standards, to help deliver an expected quality of diagnostic information. In the clinic there are checklists that must be adhered to deliver an expected level of care.
Our standardized systems are part of a natural evolution in medicine's attempts to do better.
Challenges remain for standardized terminology systems. Laboratory directors and cytopathologists must buy into the systems and use them. Further research must be done to improve these systems and provide the evidence necessary to move beyond opinion and habit.
